

Press Release

Stockholm, Sweden, September 1, 2022

Mendus to participate in upcoming conferences in September

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell-based immunotherapies, today announced its participation in the following upcoming conferences:

LSX Nordic Congress 2022

Copenhagen, Denmark, September 6-7, 2022

Mendus CEO Erik Manting will present on September 6th, 2022, at 3:30 pm CET as part of the “Investable-Showcase” track.

<https://www.lsxleaders.com/lxx-nordic-congress>

Pareto Securities’ 13th Annual Healthcare Conference

Stockholm, Sweden, September 7-8, 2022

Mendus CEO Erik Manting will present on September 8th, 2022, at 2:30 pm CET.

<https://paretosec.com/updates/events-and-conferences/>

Sachs 22nd Annual Biotech in Europe Forum

Basel, Switzerland, September 21-22, 2022

Mendus CEO Erik Manting will participate in the “Immuno-Oncology BD & Partnering” panel discussion on Wednesday, 21st of September.

<https://www.sachsforum.com/22bef-about.html>

HollandBIO and Onco Institute’s “Next Frontiers in Cancer Vaccines” Event

Amsterdam, The Netherlands, September 28, 2022

Mendus CEO Erik Manting will present at 3:10 pm CET.

<https://www.hollandbio.nl/event/biotech-wednesday-next-frontiers-in-cancer-vaccines-2/>

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

INVESTOR RELATIONS

Julie Seidel
Stern Investor Relations
Telephone: +1 212-362-1200
E-mail: julie.seidel@sternir.com

MEDIA RELATIONS

Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu

ABOUT MENDUS AB (PUBL)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <http://www.mendus.com/>